Trial Identifier: | ATX-MAP-001 |
Sponsor: | AstraZeneca |
Start Date: | February 2018 |
Primary Completion Date: | October 2024 |
Study Completion Date: | October 2024 |
Condition: | Cancer - Other |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
No documents have been posted yet.
Country | Location |
---|---|
Spain | Barcelona, Spain, 08908 |
Spain | Barcelona, Spain, 08036 |
Spain | Madrid, Spain, 28040 |
Spain | Madrid, Spain, 28050 |
United Kingdom | Glasgow, United Kingdom, G51 4TF |
United Kingdom | Leeds, United Kingdom, LS9 7TF |
United Kingdom | London, United Kingdom, NW1 2PG |
United Kingdom | London, United Kingdom, SW3 6JJ |
United Kingdom | London, United Kingdom, SE1 9RT |
United Kingdom | London, United Kingdom, NW3 2QG, |
United Kingdom | London, United Kingdom, SW3 6NP |
United Kingdom | Manchester, United Kingdom, M23 9LT |
United Kingdom | Newcastle Upon Tyne, United Kingdom, NE7 7DN |
United Kingdom | Southampton, United Kingdom, SO16 6YD |
United Kingdom | Uxbridge, United Kingdom, UB9 6JH |
United States, New York | New York, United States, 10065 |
United States, North Carolina | Durham, North Carolina, United States, 27710 |
United States, Washington | Georgetown, Washington, United States, 20057 |